Abstract Over the past few decades, understanding of the pathogenesis of rheumatoid arthritis (RA) has improved substantially. Insights into the cellular and molecular mechanisms involved in RA have enabled the discovery of new therapeutic targets and led to the development of biologics and targeted synthetic disease‐modifying antirheumatic drugs. In parallel with the improvement in therapies, the evolution of strategies in the management of RA has also contributed considerably to better outcomes in patients. Major changes include the development of disease activity measures, formulation of the treat‐to‐target principles as well as increased attention to comorbidities. The presence of comorbidities such as cardiovascular diseases may increase the mortality of RA patients, affect their treatment strategies and result in worse outcomes. Therefore, prevention and management of certain high‐risk comorbidities have become increasingly important in the long‐term treatment of RA. In this study, we summarized new insights into the pathogenesis and management of rheumatoid arthritis and associated comorbidities, with a special focus on the 2021 update of the American College of Rheumatology (ACR) guideline for RA and key reports presented at the 2021 ACR convergence. Key points The 2021 American College of Rheumatology guideline for rheumatoid arthritis (RA) provided updated recommendations on the use of disease‐modifying antirheumatic drugs, with a special focus on patients with certain high‐risk comorbidities, and reflected changes in the treatment of RA. Single‐cell sequencing, a novel technique capable of revealing the genomes and transcriptomes of individual cells, has been applied to reveal the underlying pathogenesis of RA. Risk evaluation and management of key comorbidities in RA, such as cardiovascular diseases, osteoporosis, malignancies, and infections have gained increasing attention in the research of RA. Selective JAK1 inhibitors showed promising results in both efficacy and safety in new reports from clinical trials. Further research is required to judge their optimal position in the treatment of RA. In this study, we summarized new insights into the pathogenesis and management of rheumatoid arthritis and associated comorbidities, with a special focus on the 2021 update of the American College of Rheumatology (ACR) guideline for rheumatoid arthritis and key reports presented at the 2021 ACR convergence.
New insights into the pathogenesis and management of rheumatoid arthritis
[Category] 대상포진,
[Article Type] article
[Source] pmc
All Keywords